Loading clinical trials...

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma | Clinical Trials | Clareo Health

TERMINATEDPHASE2

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

NCT01108458•George Albert Fisher

View on ClinicalTrials.gov

Summary

A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma

Detailed Description

A single-institution, single-arm phase 2 study investigating pertuzumab and erlotinib as a palliative regimen in the treatment of locally-advanced or metastatic pancreatic adenocarcinoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•3.1.1 Histologically-confirmed pancreatic adenocarcinoma
•3.1.2 One or more locally-advanced or metastatic lesions measurable in at least one dimension by modified RECIST criteria (v1.1)\^13 within 4 weeks prior to entry of study
•3.1.3 Prior therapy (1 or more):
•3.1.3.1 Disease progression following therapy with gemcitabine
•3.1.3.2 Intolerance to gemcitabine
•3.1.3.3 Disease recurrence within 12 months following adjuvant gemcitabine
•3.1.4 Age \>= 18
•3.1.5 ECOG performance status 0-2
•3.1.6 Laboratory values \<= 2 weeks prior to enrollment:
•Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L (\>= 1500/mm\^3)
+22 more criteria

Exclusion Criteria

•3.2.1 Prior therapy with EGFR-targeted agents
•3.2.2 If history of other primary cancer, subject will be eligible only if she or he has:
•Curatively resected non-melanomatous skin cancer
•Curatively treated cervical carcinoma in situ
•Other primary solid tumor curatively treated with no known active disease present and no treatment administered for the last 3 years

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Key Dates

Start Date

July 1, 2010

Primary Completion Date

November 1, 2010

Completion Date

March 1, 2011

Last Updated

March 3, 2017

Enrollment

ACTUAL participants

Conditions

Pancreatic Cancer

Interventions

Pertuzumab

DRUG

Erlotinib

DRUG

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1/PHASE2

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients